YANGON, JUNE 2019: In collaboration with KTZ, sole distributor of CCL in Myanmar, CCL Pharmaceuticals recently participated in the Myanmar Endocrine and Diabetes Conference held in Yangon, Myanmar as silver sponsor. As part of conference, CCL had arranged a symposium on Hypertension and Cardiovascular Risk in Diabetes Mellitus. The conference was attended by above 500 local and international doctors; experts delivered lectures on latest updates and guidelines of diabetes management.
CCL’s symposium was chaired by Prof. Myint Han, Director General Ministry of Health & Sports and Prof. Aung Gyi Head of Medicine, University of Medicine Mandalay. Clinical discussion on the said topic was led by Prof. Ko Ko, Head of Department North Okkalapa Hospital Yangon. Dr. Khin Swe Myint, Consultant Physician UK briefed the audience about the Endocrine Hypertension (Adrenal) with the support of 4 different case studies.
Over 400 participants visited the CCL stand in the event and appreciated the proactive approach of CCL for launching new molecule Linagliptin in Myanmar. Potential of SGLT2 inhibitors was also discussed with them and they were briefed about the upcoming new launches of SGLT2 inhibitors from platform of CCL in Myanmar.
